Onco-Innovations and Nanosoft Polymers Collaborate on Drug Delivery Development

Onco-Innovations Limited announced a non-binding Letter of Intent (LOI) with Nanosoft Polymers for advancement in polymer and drug delivery development for ONC010, a PNKP Inhibitor Technology. The LOI aims to negotiate future agreements for polymer process development and drug formulation optimization. This collaboration focuses on polymer synthesis, analytical characterization, and other development activities essential for potential GMP manufacturing.

Nanosoft Polymers, led by Dr. Xiaobing Xiong, offers expertise in functional polymers and nanoparticle-enabled drug delivery. The partnership seeks to enhance scalability, reproducibility, and regulatory preparation for ONC010, according to Thomas O'Shaughnessy, CEO of Onco-Innovations. Furthermore, Dr. Islam Mohamed, the company's Chief Medical Officer, emphasized the integration of polymer science with nanoparticle-based oncology therapeutics.

Additionally, Onco-Innovations appointed Dave Antony as Vice President of Corporate Finance, bringing extensive experience in financial planning and corporate governance. His background is expected to support the company's oncology-focused development strategy and capital market engagements.